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Summary
 
The earliest contact between antigen and the innate immune system is thought to direct the
subsequent antigen-specific T cell response. We hypothesized that cells of the innate immune
system, such as natural killer (NK) cells, NK1.1
 
1
 
 T cells (NKT cells), and 
 
g
 
/
 
d
 
 T cells, may reg-
ulate the development of allergic airway disease. We demonstrate here that depletion of
NK1.1
 
1
 
 cells (NK cells and NKT cells) before immunization inhibits pulmonary eosinophil
and CD3
 
1
 
 T cell infiltration as well as increased levels of interleukin (IL)-4, IL-5, and IL-12 in
bronchoalveolar lavage fluid in a murine model of allergic asthma. Moreover, systemic aller-
gen-specific immunoglobulin (Ig)E and IgG2a levels and the number of IL-4 and interferon
 
g
 
–producing splenic cells were diminished in mice depleted of NK1.1
 
1
 
 cells before the prim-
ing regime. Depletion of NK1.1
 
1
 
 cells during the challenge period only did not influence pul-
monary eosinophilic inflammation. CD1d1 mutant mice, deficient in NKT cells but with nor-
mal NK cells, developed lung tissue eosinophilia and allergen-specific IgE levels not different
from those observed in wild-type mice. Mice deficient in 
 
g
 
/
 
d
 
 T cells showed a mild attenua-
tion of lung tissue eosinophilia in this model. Taken together, these findings suggest a critical
role of NK cells, but not of NKT cells, for the development of allergen-induced airway inflam-
mation, and that this effect of NK cells is exerted during the immunization. If translatable to
humans, these data suggest that NK cells may be critically important for deciding whether aller-
gic eosinophilic airway disease will develop. These observations are also compatible with a
pathogenic role for the increased NK cell activity observed in human asthma.
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A
 
irway mucosal inflammation in allergic asthma is thought
to be dependent on T lymphocytes producing pro-
inflammatory cytokines (1, 2). The production of IL-4 and
IL-5 by these cells is considered to be pivotal for the recruit-
ment of eosinophils to the airways, a hallmark of asthma (3,
4). The development of T cell effectors from naive T cells
may depend on many factors, including the nature of anti-
gen presentation and the local cytokine milieu during the
period of T cell priming (5, 6). It has been suggested that
rapid generation of key cytokines by cells of the innate im-
munity regulates the subsequent antigen-specific T cell re-
sponse (7–9). Thus, cells such as NK cells, NK1.1
 
1
 
 T cells
(NKT cells),
 
1
 
 and 
 
g
 
/
 
d
 
 T cells have been given tentative
roles in determining the nature of the acquired immune re-
sponse. This possibility has been discussed particularly with
regard to host response to infection (8, 9).
NK cells are recognized as an important component in
immune responses against a number of pathogens (10, 11).
 
1
 
Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage; BALF, BAL
fluid; ELISPOT, enzyme-linked immunospot; NKT cells, NK1.1
 
1
 
 T
cells; SAL, saline; SFC, spot-forming cell. 
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Their cytokine production rather than cytolytic activity
contributes to the resistance against infectious agents (10,
11). NK cells can rapidly produce IFN-
 
g
 
. However, these
cells may also produce a variety of other immunoregulatory
mediators, including TGF-
 
b
 
, TNF-
 
a
 
, TNF-
 
b
 
, GM-CSF,
macrophage inflammatory protein (MIP)-1
 
a
 
, IL-1, IL-2,
IL-3, IL-5, IL-8, and IL-10 (10–12). In addition to NK
cells, mouse NK1.1
 
1
 
 cells comprise a small population of
cells that coexpress NK1.1 and TCR, i.e., NKT cells (13–
15). A human counterpart of the mouse NKT cell, coex-
pressing IL-4 and IFN-
 
g
 
, has recently been identified (16).
Little is known about the role of NK cells in induction
of immune responses to allergens. Bogen et al. (17) have
demonstrated that the earliest detectable response to subcu-
taneous administration of a protein antigen (OVA) in adju-
vant was the appearance of IFN-
 
g
 
–producing NK1.1
 
1
 
 cells
at the site of immunization. NK cells are normally present
in considerable numbers in human lung interstitium, sug-
gesting involvement of these cells in pulmonary immunity
(18). Furthermore, it has been demonstrated that patients
with asthma show increased numbers of NK cells and
stronger NK activity in peripheral blood than normal
healthy blood donors (19–21). NK cell activity may also be
increased after bronchial allergen challenge in asthmatic
subjects (22). However, the focus in these previous clinical
studies has been on the possible association of asthma with
a reduced risk for tumor disease development.
 
g
 
/
 
d
 
 T cells represent another lymphocyte population
that can produce various cytokines early in an immune re-
sponse. A recent study has shown that 
 
g
 
/
 
d
 
 T cells differen-
tially produce IFN-
 
g
 
 and IL-4 in response to Th1- and
Th2-inducing pathogens (23). However, the role of 
 
g
 
/
 
d
 
 T
cells in allergic diseases such as asthma is still controversial.
McMenamin et al. (24) have shown that CD8
 
1
 
 
 
g
 
/
 
d
 
 T cells
in mice may specifically downregulate IgE responses to sol-
uble OVA. Recently, Zuany-Amorim et al. (25) reported
that 
 
g
 
/
 
d
 
 T cells are required for inducing allergen-specific
IgE and IgG1 responses and Th2-mediated airway inflam-
mation in a mouse model of asthma.
We hypothesized that innate immunity, particularly NK
cells, NKT cells, and 
 
g
 
/
 
d
 
 T cells, may be involved in the
processes that cause eosinophilic airway inflammation in
immunized and allergen-exposed mice. Specifically, this
study asks whether mice that are depleted of NK1.1
 
1
 
 cells,
i.e., NK cells and NKT cells (26), and whether mice that
genetically lack NKT cells (27) or 
 
g
 
/
 
d
 
 T cells (28), develop
pulmonary inflammation in an established model of allergic
asthma (29, 30).
 
Materials and Methods
 
Animals and Study Design.
 
Male C57BL/6 mice (
 
n
 
 5 
 
127, 8–9
wk of age in experiment I and II, 4–6 mo of age in experiment
IV) were purchased from Bomholtgaard (Table I). CD1d1 mu-
tant (129/Sv 
 
3 
 
C57BL/6) mice and wild-type littermates (
 
n
 
 5
 
20, 7 wk of age) were used in experiment III (27). TCR 
 
d
 
 gene
mutant (C57BL/6) mice (
 
n
 
 5 
 
6, 6 mo of age) were purchased
from The Jackson Laboratory (28). All mice were kept in well-
controlled animal housing facilities and had free access to tap wa-
ter and pelleted food throughout the experimental period.
 
 
 
Ani-
mals were killed by intraperitoneal injection of pentobarbital 8,
24, or 30 h after the last aerosol exposure. Each group consisted
of 5–11 animals. Groups of mice were subjected to bronchoalve-
olar lavage (BAL) and/or blood sampling before lungs and spleen
were dissected out.
 
Immunization and Challenge.
 
We have used a protocol slightly
modified from that developed by Brusselle and colleagues (29).
On the first day of the experiment (day 0), all mice were actively
immunized by injection of 10 
 
m
 
g i.p. chicken OVA (Grade III;
Sigma), adsorbed to 1 mg of alum adjuvant. From days 14–15
(groups 1–4) or from days 14–20 (all other groups) after immuni-
zation, the mice were exposed daily to aerosolized saline (SAL) or
OVA over a 30-min period by placing groups of 5–12 awake
mice in an exposition chamber (Table I). The aerosols were gen-
erated into the chamber using a nebulizer (500 ml Inline Micro-
 
Table I.
 
Study Design
 
Groups
Treatment/
genotype
Start
of treat-
ment Challenge
Termina-
tion of
experi-
ment
 
dh
 
Experiment I
1 IgG
 
2
 
2 SAL 
 
3
 
28
2 mAb NK1.1
 
2
 
2 SAL 
 
3
 
28
3 IgG
 
2
 
2 OVA 
 
3
 
28
4 mAb NK1.1
 
2
 
2 OVA 
 
3
 
28
5 IgG
 
2
 
2 SAL 
 
3
 
78
6 mAb NK1.1
 
2
 
2 SAL 
 
3
 
78
7 IgG
 
2
 
2 OVA 
 
3
 
78
8 mAb NK1.1
 
2
 
2 OVA 
 
3
 
78
Experiment II
9 IgG
 
2
 
2 OVA 
 
3
 
78
10 mAb NK1.1
 
2
 
2 OVA 
 
3
 
78
11 mAb NK1.1
 
2
 
7 OVA 
 
3
 
78
12 IgG 13 OVA 
 
3
 
78
13 mAb NK1.1 13 OVA 
 
3
 
78
14 IgG
 
2
 
2 OVA 
 
3
 
73 0
15 mAb NK1.1
 
2
 
2 OVA 
 
3
 
73 0
Experiment III
16
Wild-type
(CD1
 
1
 
/
 
1
 
) – OVA 
 
3
 
78
17
CD1d1 mutant
(CD1
 
2
 
/
 
2
 
) – OVA 
 
3
 
78
Experiment IV
18 Wild-type – SAL 
 
3
 
72 4
19 Wild-type – OVA 
 
3
 
72 4
20
 
g
 
/
 
d
 
 T cell–
deficient – OVA 
 
3
 
72 4
Four independent experiments were performed and are shown sepa-
rately. All mice were immunized with OVA on day 0. 
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nebulizer driven at 4 bar; Bird Co.). The concentration of OVA
in the nebulizer was 1% wt/vol.
 
Depletion of NK1.11 Cells. To deplete NK1.11 cells in vivo,
mice were injected starting 2 d before immunization with 100 mg
i.p. of anti-NK1.1 mAb (26), and every 5 d thereafter with 25 mg
i.p. of the anti-NK1.1 mAb until termination of the experiment.
One group of mice was depleted of NK1.11 cells in a similar
manner, but the treatment regimen started 7 d before immuniza-
tion (group 11). A third group of animals was also depleted of
NK1.11 cells, but the treatment started 1 d before first allergen
aerosol challenge (group 13). Control mice were injected with a
similar volume (0.2 ml) and dose of mouse IgG antibody (Sigma)
as the appropriate isotype control. The efficacy of depletion of
NK1.11 cells was monitored by flow cytometric analysis of
spleen cells at the end of the experimental period. Animals exhib-
iting .1.0% NK1.11 cells in the spleen at the end of the experi-
ment were excluded from the study (n 5 5).
Histochemistry. Lung tissue specimens obtained 8, 24, and 30 h
after the last OVA or SAL exposure were immersed overnight in
Stefanini’s fixative (2% paraformaldehyde and 0.2% picric acid in
0.1 M phosphate buffer, pH 7.2), rinsed repeatedly in buffer (Ty-
rode buffer supplemented with 10% sucrose), frozen in mounting
medium (Tissue-Tek; Miles, Inc.), and stored at 2808C until sec-
tioning. Eosinophils were detected by histochemical visualization
of cyanide-resistant eosinophil peroxidase activity (31). In brief,
cryosections (10 mm) were incubated for 8 min at room tempera-
ture in PBS buffer (pH 7.4) supplemented with 3,3-diaminoben-
zidine tetrahydrochloride (60 mg/100 ml; Sigma), 30% H2O2 (0.3
ml/100 ml), and NaCN (120 mg/100 ml). Slides were then rinsed
in water and mounted in Kaiser’s medium (Merck). Eosinophils
were identified by their dark brown reaction product. For his-
tochemical detection of mucus-containing cells in lungs, 10-mm
cryosections were stained with periodic acid-Schiff reagent (PAS).
Distinct purple-red granules could be observed in the mucus-con-
taining cells. For assessment of general airway morphology, sec-
tions were stained with hematoxylin and erythrosin.
Immunohistochemistry. Cryosections (10 mm) were fixed in
cold acetone diluted 1:2 in distilled water for 30 s, followed by fi-
nal fixation in cold acetone (100%) for 5 min. Subsequent
incubations were carried out sequentially for 30 min, with 5 min
in PBS between each step. Unspecific antibody binding was
blocked by incubation with PBS containing 10% (vol/vol) nor-
mal rabbit serum for 5 min (X0902; Dako). Incubation with an
mAb recognizing the mouse CD3 antigen (clone KT3; Serotec)
was followed by rabbit anti–rat IgG antibody (Z494; Dako) di-
luted 1:50 in PBS containing 10% (vol/vol) normal rabbit serum.
After a final incubation with a monoclonal rat alkaline phos-
phatase–anti-alkaline phosphatase reagent (D488; Dako), the al-
kaline phosphatase reaction was developed using BCIP/NBT/
INT mixed with Levamisole (K599 and X3021; Dako) for 10 min.
Analysis of Cytokines in BAL Fluid. All mice in experiments I
and III and groups 12 and 13 in experiment II were subjected to
BAL at 8 h after last aerosol exposure (Table I). After the animals
had been anesthetized with an intraperitoneal injection of pento-
barbital, a tracheal cannula was inserted via a midcervical incision
and the airways were lavaged twice with 0.9 ml of PBS (Life
Technologies). The BAL fluid (BALF) was immediately centri-
fuged (10 min, 48C, 160 g), and the supernatant was rapidly fro-
zen. Commercial ELISA kits were used to measure levels of IL-4
(Biosource International), IL-5 (Nycomed Amersham plc), IL-12
(Genzyme), and IFN-g (Biosource International) in the BALF.
The limit of detection was 5 pg/ml for IL-4 and IL-5, 10 pg/ml
for IL-12, and 1 pg/ml for IFN-g.
Measurement of OVA-specific IgE and IgG2a in Plasma. Blood
was drawn from all mice in experiments II–IV (Table I) by car-
diac puncture and placed in EDTA tubes. After centrifugation,
the plasma samples were rapidly frozen. OVA-specific IgE and
IgG2a levels were determined by sandwich ELISA in 96-well
ELISA plates. Sample wells were coated overnight with OVA
grade III (100 mg/ml, 100 ml/well; Sigma). Wells were then
blocked with 3% BSA in PBS (200 ml/well) at 378C for 2 h. Di-
luted samples and standard (100 ml/well) were incubated over-
night at 48C. Plates were washed with 0.05% Tween 20/PBS and
incubated with biotin-conjugated anti–mouse IgE (diluted 1:500)
or IgG2a (diluted 1:100, 100 ml/well; PharMingen) at room tem-
perature for 90 min. After another wash procedure, plates were
incubated for 90 min at room temperature with 100 ml/well of
ExtrAvidin-HRP (Sigma) diluted 1:600 in 1% BSA/PBS. Plates
were developed with TMB Microwell Peroxidase Substrate (100
ml/well; Kirkegaard & Perry Labs). Plates were read at 450 nm. A
plasma pool of OVA-immunized mice was used as internal labo-
ratory standard. A 1:100 dilution of this pool was chosen as arbi-
trary unit.
Enzyme-linked Immunospot Analysis of Cytokine-producing Spleen
Cells. The number of spleen cells producing IL-4 and IFN-g
was evaluated in groups 9 and 10, 14 and 15, and 16 and 17 (Ta-
ble I). Spleens were rapidly dissected out and placed in ice-cooled
RPMI 1640 medium (Life Technologies). The enzyme-linked im-
munospot (ELISPOT) method was carried out the following day
essentially as described elsewhere (32). Purified primary antibodies
for IFN-g (R4-6A2) and for IL-4 (BVD4-1D11) obtained from
Nordic Biosite were diluted to 15 mg/ml in PBS and coated to plas-
tic plates (Dynatech). The plates were washed, and Con A–stimu-
lated (2.5 mg/ml; Sigma), OVA-stimulated (10 mg/ml, Grade III;
Sigma), or unstimulated cells were added at suitable concentrations
and incubated overnight at 378C in 5% CO2. After washing, the
plates were incubated with secondary biotinylated antibodies diluted
in PBS to 1 mg/ml specific for IFN-g (XMG1.2; Nordic Biosite)
and IL-4 (BVD6-24G2; Nordic Biosite), respectively. After incuba-
tion at 48C overnight, the plates were washed, avidin–alkaline phos-
phatase (Dako) was added, and after 2 h in room temperature and
further washing, BCIP phosphatase substrate solution (Sigma) was
added and the plates were developed. Spots in each well were
counted with a reversed microscope. The number of CD31 spleen
cells was determined, and the cytokine response was expressed as the
number of spot-forming cells (SFCs)/CD31 cells.
Quantification and Statistics. For evaluation of the number of
eosinophils and CD31 cells in pulmonary tissue, 40 randomly se-
lected areas (0.04 mm2 each) in 1 lung section from each animal
were examined. The number of eosinophils and CD31 cells in
the 40 areas was counted at a magnification of 400, and the mean
was expressed as eosinophils or CD31 cells per unit area. All
quantifications were performed blind. Data are expressed as mean 6
SEM unless otherwise indicated. To calculate significance levels
between treatment groups, the Student’s t test was used through-
out the study. Values below detection limits were assigned the
value of the detection limit. To achieve comparable SDs, ELISA
values were transformed to logarithms before statistical analysis.
Probabilities ,0.05 were used as the generally accepted level of
statistical significance for differences between mean values.
Results
Early Allergen-induced Airway Changes in Mice Depleted of
NK1.11 Cells before Immunization. Histologic analysis of556 Innate Immunity May Decide Development of Allergic Airway Inflammation
lungs taken 8 h after last (second) aerosol exposure from
both IgG-treated and NK1.11 cell–depleted mice receiving
two OVA challenges (groups 3 and 4) exhibited a slight
pulmonary eosinophilia (3.9 6 1.0 and 3.8 6 0.7 cells/unit
area, respectively). Although a few small eosinophilic infil-
trates were detected in lung tissue in the majority of these
animals, the eosinophilia was not significantly increased
compared with corresponding immunized and SAL-exposed
animals (2.2 6 0.4 and 2.3 6 0.4 cells/unit area, respec-
tively). To detect the emerging Th2 response in the lungs
of these animals after allergen exposure, we measured IL-4
in BALF using ELISA. The levels of IL-4 in BALF were
increased in immunized and OVA-challenged IgG-treated
mice compared with corresponding immunized and SAL-
exposed animals (142.7 6 14.8 vs. 89.7 6 19.7 pg/ml; P ,
0.05). A tendency towards higher IL-4 levels in NK1.11
cell–depleted animals compared with IgG-treated mice was
demonstrated. Thus, IL-4 levels in BALF from OVA-chal-
lenged and NK1.11 cell–depleted mice did not differ sig-
nificantly from those in the corresponding SAL-exposed
group (159.0 6 25.2 vs. 131.4 6 7.4 pg/ml).
Late Allergen-induced Airway Changes in Mice Depleted of
NK1.11 Cells before Immunization. Immunized and IgG-
treated mice receiving seven OVA challenges exhibited at
the 8 h time point a marked eosinophilia perivascularly and
peribronchially in the lung (groups 7 and 9; Fig. 1, a and b,
and Fig. 2 a). In contrast, corresponding mice depleted of
NK1.11 cells (groups 8 and 10) showed a clearly inhibited
eosinophilia in lung tissue (Fig. 1, a and b). These mice ex-
hibited a few scattered eosinophilic infiltrates, or a complete
absence of pulmonary inflammation (Fig. 2 b). Eosinophilic
infiltrates were not observed in lung tissue from SAL-exposed
mice of either the IgG-treated or the NK1.11 cell–depleted
groups (groups 5 and 6; Fig. 1 a). The marked attenuation of
lung tissue eosinophilia in mice depleted of NK1.11 cells was
still observed 30 h after the last OVA exposure (group 15;
Fig. 1 b). At this time point, one outlier (determined by Q
test) was obvious, without which the difference between
IgG-treated and depleted animals had been statistically signifi-
cant (P , 0.05). It is possible that this single animal (exhibit-
ing the second most pronounced pulmonary eosinophilia in
the experiment) was not successfully depleted of NK1.11
cells after the first injection of mAb NK1.1, 2 d before immu-
nization.
The number of CD31 cells in lung tissue from immu-
nized and IgG-treated animals receiving seven OVA chal-
lenges was increased compared with corresponding immu-
nized and SAL-exposed animals at the 8-h time point (12.0 6
2.0 vs. 5.1 6 0.4 cells/unit area; P , 0.05). In contrast, the
number of CD31 cells in lung tissue from immunized and
NK1.11 cell–depleted animals remained low after allergen
challenges (6.7 6 1.0 vs. 6.8 6 1.4 cells/unit area in corre-
sponding SAL-exposed animals).
Figure 1. (a and b) Effect of depleting NK1.11 cells before immuniza-
tion on lung tissue eosinophilia. Mice were immunized on day 0 and
challenged daily with aerosolized OVA or SAL on days 14–20. The ani-
mals were killed 8 or 30 h after last challenge. In two independent exper-
iments, mice received mAb NK1.1 treatment. The first experiment (a)
involved BAL, which may change the cellular composition in the lung
tissue. Therefore, the two experiments are shown separately. Solid bars,
mean (n 5 5–8 in each group); OVA, OVA-challenged animals; SAL,
SAL-challenged animals; IgG, IgG-treated animals; NK1.1, mAb NK1.1–
treated animals. In a, *P , 0.05 between OVA- and SAL-challenged
mice. In b, ***P , 0.001 between OVA-challenged IgG-treated and
NK1.11 cell–depleted mice. At the 30-h time point, one outlier in the
NK1.11 cell–depleted group was demonstrated (determined by Q test),
without which the difference between IgG-treated and depleted animals
had been statistically significant (P , 0.05).
Figure 2. Effect of depleting NK1.11 cells before immunization on the
development of eosinophilic pulmonary inflammation. Animals were im-
munized and repeatedly challenged to aerosolized OVA (seven times). 8 h
after last exposure, lungs were processed for histologic analysis. Eosino-
phils are visualized by histochemical demonstration of cyanide-resistant
eosinophil peroxidase activity. Multifocal perivascular and peribronchial
eosinophilic distribution in the lung tissue is seen in immunized and IgG-
treated mice 8 h after last OVA exposure (a). Corresponding mice de-
pleted of NK1.11 cells exhibited a few scattered eosinophilic infiltrates
only (b), or a complete absence of pulmonary inflammation (not shown).
B, bronchus; V, blood vessel. Bar, 150 mm.557 Korsgren et al.
Sections stained with hematoxylin and erythrosin or PAS
further demonstrated that the pulmonary eosinophilia was
accompanied by a dense infiltration of mononuclear cells
and an evident increase in airway epithelial mucus cells in
lungs of OVA-exposed IgG-treated mice. Also, these mor-
phological changes were markedly reduced in OVA-chal-
lenged mice depleted of NK1.11 cells.
To determine the type of immune response (Th1 and/or
Th2) being induced in the airways of immunized mice after
multiple allergen aerosol exposures, we measured cytokines
in BALF taken 8 h after last aerosol exposure. The levels
of IL-4 in BALF were similar in both IgG-treated and
NK1.11 cell–depleted mice receiving seven OVA chal-
lenges compared with corresponding SAL-exposed animals
(Fig. 3). Thus, the increased levels demonstrated after two
OVA exposures in immunized IgG-treated mice (but not
in corresponding mice depleted of NK1.11 cells) were not
detected under these more chronic conditions. BALF from
IgG-treated mice receiving seven allergen challenges con-
tained measurable amounts of IL-5 (P , 0.05, compared
with SAL-exposed IgG-treated animals; Fig. 3). In contrast,
NK1.11 cell–depleted animals failed to release IL-5 after
OVA exposure (Fig. 3). The levels of IL-12 in BALF in-
creased after allergen exposure in IgG-treated animals (P ,
0.001, compared with corresponding SAL-challenged ani-
mals; Fig. 3). In contrast, IL-12 levels in BALF from
NK1.11 cell–depleted mice remained low in response to
allergen exposure, similar to the levels in corresponding
SAL-exposed animals. The levels of IFN-g in BALF de-
creased after allergen challenge to values very near or be-
low the detection limit of the assay in five out of seven
IgG-treated animals (Fig. 3). Interestingly, the two animals
exhibiting high IFN-g values showed undetectable IL-5
levels in BALF and no pulmonary eosinophilia. OVA chal-
lenge of mice depleted of NK1.11 cells caused a moderate
decrease in levels of IFN-g (P , 0.05, compared with cor-
responding SAL-exposed mice; Fig. 3).
Systemic Allergen-specific IgE and IgG2a Levels in Mice De-
pleted of NK1.11 Cells before Immunization.  To assess the
peripheral immune response to immunization and allergen
challenge, we measured OVA-specific IgE and IgG2a levels
in plasma using ELISA. Immunization and allergen expo-
sure of IgG-treated animals induced both OVA-specific
IgE and IgG2a (Fig. 4). In corresponding NK1.11 cell–
depleted animals, this induction of OVA-specific IgE and
IgG2a was significantly suppressed (P , 0.01, P , 0.05,
compared with immunized and OVA-challenged mice
treated with IgG).
Cytokine Production by Spleen Cells after Allergen Challenge
in Mice Depleted of NK1.11 Cells before Immunization. To
estimate the systemic T cell cytokine response in spleen af-
ter immunization and OVA challenge, we used ELISPOT.
The number of IL-4–producing spleen cells (both unstimu-
lated and OVA-stimulated cells) was overall lower in mice
depleted of NK1.11 cells compared with IgG-treated ani-
mals (Fig. 5, a and b). The number of OVA-stimulated
Figure 3. Effect of depleting NK1.11 cells before immunization on
BALF cytokine levels 8 h after last OVA or SAL exposure. Mice were
immunized on day 0 and challenged daily with aerosolized OVA or SAL
on days 14–20. Solid bars, mean (n 5 5–8 per group); OVA, OVA-chal-
lenged animals; SAL, SAL-challenged animals; IgG, IgG-treated animals;
NK1.1, mAb NK1.1–treated animals. Dotted lines, detection limit of the
assays. *P , 0.05, ***P , 0.001.
Figure 4. Effect of depleting NK1.11 cells before immunization on sys-
temic levels of OVA-specific IgE and IgG2a. Mice were immunized on
day 0 and challenged daily with aerosolized OVA on days 14–20. Plasma
was collected 8 or 30 h after last OVA challenge. Immunization and aller-
gen exposure of IgG-treated animals induced both allergen-specific IgE
and IgG2a. In corresponding NK1.11 cell–depleted animals, this induction
of allergen-specific IgE and IgG2a was significantly suppressed (**P , 0.01
and *P , 0.05, respectively). Solid bars, mean (n 5 13–14 per group);
IgG, IgG-treated animals; NK1.1, mAb NK1.1–treated animals.558 Innate Immunity May Decide Development of Allergic Airway Inflammation
IL-4–producing cells at the 8-h time point was significantly
lower in NK1.11 cell–depleted mice compared with IgG-
treated animals (P , 0.05). Similar patterns were obtained
for IFN-g–producing cells (Fig. 5, a and b). Significant dif-
ferences were obtained at the 8- and 30-h time points be-
tween the number of unstimulated IFN-g–producing
spleen cells from IgG-treated and NK1.11 cell–depleted
animals (P , 0.05).
Allergen-induced Changes in Mice Depleted of NK1.11 Cells
during the Challenge Period Only. To determine if NK1.11
cells are required for the initiation of the immune response
at the time of immunization or for the onset of pulmonary
inflammation secondary to allergen challenge, mice were
depleted of NK1.11 cells during the challenge period only
(group 13). Immunization and OVA exposure (seven
times) of mice depleted of NK1.11 cells during the chal-
lenge period only led to the development of a pulmonary
eosinophil-rich inflammation similar to that observed in
corresponding IgG-treated animals (26.3 6 3.9 and 19.5 6
2.5 eosinophils/unit area, respectively). These groups of
mice also exhibited similar levels of IL-4 (70.9 6 8.8 and
85.6 6 20.9 pg/ml, respectively), IL-12 (1,524.5 6 137.1
and 1,184.5 6 202.1 pg/ml, respectively), and IFN-g (lev-
els , detection limit in both groups) in BALF. Further-
more, systemic levels of OVA-specific IgE were not altered
(4,132.3 6 1,661.3 versus 6,281.0 6 2,563.6 U/ml in the
corresponding IgG-treated group).
Allergen-induced Changes in Mice Depleted of NK1.11 Cells
7 d before Immunization. To confirm that no acute non-
specific effects (such as cytokine release) of depletion with
mAb NK1.1 caused the demonstrated effects on the im-
mune response, mice were depleted of NK1.11 cells from
day –7 before immunization (group 11). This group of
mice exhibited a reduction of lung tissue eosinophilia com-
pared with mice treated with IgG from day 22 before im-
munization (group 9) (14.2 6 2.4 vs. 25.9 6 3.7 cells/unit
area; P , 0.05). Also, these mice exhibited suppressed lev-
els of OVA-specific IgE compared with mice treated with
IgG from day –2 before immunization (group 9) (1,133.7 6
428.8 vs. 6,971.1 6 4,735.1 U/ml; P , 0.05). Depletion
of NK1.11 cells from day 27 before immunization also
suppressed OVA-specific IgG2a levels. In this group, all
mice had levels of IgG2a below detection limit (P , 0.05,
compared with mice treated with IgG from day –2 before
immunization).
Allergen-induced Changes in Mice Deficient in NKT Cells.
To elucidate if the suppression of the allergic immune re-
sponse seen after NK1.11 cell depletion requires NK cells
or NKT cells, CD1d1 mutant mice, which selectively lack
NKT cells (group 17), were immunized and OVA chal-
lenged. Immunization and OVA exposure (seven times) of
mice deficient in NKT cells led to the development of a
pulmonary eosinophil-rich inflammation similar to that ob-
served in corresponding wild-type animals (Fig. 6). CD1d1
mutant and wild-type mice also exhibited similar levels
of OVA-specific IgE (4,342.9 6 1,054.3 and 6,814.8 6
2,702.9 U/ml, respectively). The numbers of IL-4– and
IFN-g–producing spleen cells in immunized and allergen-
challenged CD1d1 mutant and wild-type mice were deter-
mined by the ELISPOT method. There was a tendency,
although statistically insignificant, of reduced numbers
of IL-4–producing unstimulated and OVA-stimulated
Figure 5. (a and b) Cytokine production by splenic cells after allergen
challenge in IgG-treated and NK1.11 cell–depleted mice. Mice were im-
munized on day 0 and challenged daily with aerosolized OVA on days
14–20. Mean (6 SEM) numbers of IFN-g (white bars) and IL-4 (black
bars) spot-forming spleen cells (SFCs)/106 cells. The numbers of SFCs for
unstimulated cells (a) and the numbers of SFCs for cells stimulated with
OVA (b) are shown. IgG, IgG-treated animals; NK1.1, animals depleted
of NK1.11 cells. *P , 0.05.
Figure 6. CD1d1 (CD12/2)
mutant mice and wild-type con-
trols (CD11/1) were immunized
on day 0 and challenged daily
with aerosolized OVA on days
14–20. The number of eosino-
phils in lung tissue was similar in
both groups of mice. Solid bars,
mean (n 5 9–11 per group).559 Korsgren et al.
spleen cells from CD1d1 mutant mice compared with
wild-type mice (5.4 6 1.2 vs. 16.2 6 6.0 SFCs/106 CD31
unstimulated cells and 150.0 6 27.1 vs. 418.2 6 212.8
SFCs/106 CD31 OVA-stimulated cells). The number of
unstimulated IFN-g–producing cells was increased in
CD1d1 mutant mice compared with wild-type mice (60.0 6
17.2 vs. 15.4 6 7.8 SFCs/106 CD31 cells; P , 0.05).
There was also a tendency of increased numbers of OVA-
stimulated IFN-g–producing cells from mutant mice com-
pared with wild-type animals (134.4 6 54.1 vs. 40.9 6
11.9 SFCs/106 CD31 cells).
Allergen-induced Changes in Mice Deficient in g/d T Cells.
A moderate reduction, although statistically insignificant, of
lung tissue eosinophilia was observed in OVA-challenged
g/d T cell–deficient animals compared with corresponding
wild-type mice (Fig. 7). Similarly, no significant difference
in systemic levels of OVA-specific IgE was observed be-
tween OVA-challenged g/d T cell–deficient animals and
corresponding wild-type mice (1,066.3 6 314.5 and
2,567.4  6 1,497.1 U/ml, respectively).
Discussion
This study demonstrates that depletion of NK1.11 cells
(NK cells and NKT cells) before the priming regime inhib-
its pulmonary eosinophil and CD31 T cell infiltration as
well as increased levels of IL-4, IL-5, and IL-12 in BALF in
a murine model of allergic asthma. Consistent with the
suppression of allergic airway inflammation seen in mice
depleted of NK1.11 cells before immunization, i.e., during
the initiation of the acquired immune response, diminished
systemic levels of OVA-specific IgE and IgG2a and im-
paired T cell cytokine production in spleen were observed
in these mice. The demonstration of a marked eosinophil-
rich inflammation in lung tissue of NKT cell–deficient
CD1d1 mutant mice strongly supports an important role of
NK cells, but not of NKT cells, for development of aller-
gen-induced pulmonary inflammation. However, we can-
not completely exclude the possibility that NK cells and
NKT cells somehow interact and that depletion of both
cell types may be required for inhibition of the allergic im-
mune response in this model. A recent study has shown
that allergen-specific IgE and IgG1 responses and allergic
airway inflammation, induced by repeated immunization
and intranasal allergen challenges, are reduced in g/d T
cell–deficient mice (25). In our experimental model, aller-
gen-induced changes in g/d T cell–deficient animals were
attenuated, but this effect was moderate compared with the
marked suppression of the allergic airway inflammation
demonstrated in mice depleted of NK1.11 cells. Together,
these data support the hypothesis that innate immunity reg-
ulates the acquired immune response in allergic inflamma-
tion. Given the caution required in any translation of find-
ings in murine allergic models to human asthma (33), the
present observations suggest the possibility that human NK
cells may govern development of allergic eosinophilic air-
way disease.
The present protocol for immunization and allergen
aerosol challenge was adopted from Brusselle et al. (29). In
this mouse model of asthma, repeated daily exposure of im-
munized mice to aerosolized OVA leads to a CD41 T cell–
dependent (29) and IL-4–dependent (29, 34) eosinophilic
inflammation with increased secretory cell epithelial lining
(30), lung and splenic Th2 cytokine production (35; this
study), and systemic allergen-specific IgE production (29,
34, 35; this study), consistent with a Th2-associated im-
mune response. However, indices not only of Th2 expan-
sion but also of Th1 expansion are present in this model.
Thus, systemic OVA-specific IgG2a production and in-
creased levels of IL-12 in BALF were demonstrated in im-
munized and repeatedly allergen-challenged mice. Also in
allergic asthma there may be a mixed Th2/Th1 response.
Although there is a predominance of IL-4– and IL-5–pro-
ducing CD41 T cells, a population of IFN-g–producing
CD41 T cells has thus been demonstrated in BALF from
asthmatic subjects (1, 36).
It may be hypothesized that the suppressed allergic re-
sponse in mice depleted of NK1.11 cells is caused by defi-
cient IL-4 production at the time of immunization. Studies
have failed to detect IL-4 production by NK cells (12).
However, it has been hypothesized that NKT cells may be
an important source of IL-4 and, according to the paradigm
of Th1 and Th2 (37), for the development of Th2 immune
responses (38–40). Accordingly, in this study, spleens of
NKT cell–deficient CD1d1 mutant mice exhibited a ten-
dency of reduced numbers of IL-4–producing CD31 T
cells and an associated increase in IFN-g–producing CD31
T cells. However, since CD1d1 mutant mice developed
lung tissue eosinophilia and allergen-specific IgE levels not
different from those observed in wild-type mice, we con-
clude that NKT cells and their swift production of IL-4 are
not critical for the allergic responses in this model. Also,
previous studies using b2-microglobulin–deficient animals
have shown that NKT cells are dispensable for allergen-
induced Th2 responses in the airways (41, 42).
Our data on systemic levels of OVA-specific IgE and
IgG2a in NK1.11 cell–depleted mice are in contrast to
Figure 7. Number of eosino-
phils in lung tissue from immu-
nized wild-type and g/d T cell–
deficient animals receiving seven
exposures with OVA or SAL.
Solid bars, mean (n 5 6 per
group); SAL g/d1/1, SAL-chal-
lenged wild-type mice; OVA g/
d1/1, OVA-challenged wild-
type mice; OVA gd2/2, OVA-
challenged  g/d T cell–deficient
animals. An increased number of
eosinophils in lung tissue was
observed in OVA-challenged
wild-type mice compared with
corresponding SAL-exposed ani-
mals (**P , 0.01). No significant
difference was observed between
OVA-challenged wild-type mice
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those reported recently by Wang et al. (43). In their study,
depletion of NK1.11 cells altered neither OVA-specific
IgE and IgG2a levels nor OVA-stimulated cytokine pro-
duction by spleen cells in bulk culture in immunized mice
(43). There are no obvious explanations for this discrep-
ancy. However, since they delivered the mAb NK1.1 on
the day of immunization, it can be speculated that the lack
of immune suppression may in part have been caused by
antibody-induced nonspecific production of cytokines dur-
ing the initiation of the immune response. Thus, Asea et al.
(44) demonstrated recently that a single delivery (50 mg
i.v.) of mAb NK1.1 triggered a population of NKT cells to
produce IL-4 within 90 min. This production returned to
baseline levels by 24 h after antibody treatment. To con-
firm that no acute nonspecific effects (such as cytokine re-
lease) of depletion with mAb NK1.1 on day –2 caused the
effects on immunization in this study, mice were depleted
of NK1.11 cells from day –7 before immunization. These
mice also exhibited suppressed pulmonary eosinophilia and
decreased systemic levels of IgE and IgG2a. In another
control experiment, the efficacy of depletion of NK1.11
cells from day –7 and from day –2 was monitored by flow
cytometric analysis of spleen cells at the day of immuniza-
tion. All antibody-treated mice (n 5 10) exhibited ,1%
NK1.11 cells in the spleen at this time point (our unpub-
lished data).
The critical role of NK cells in this model of allergic
asthma is limited to the immunization phase, as depletion
of NK1.11 cells during the challenge period only did not
influence the magnitude of pulmonary eosinophilia, levels
of OVA-specific IgE, and cytokines in BALF. Thus, it ap-
pears likely that NK cells influence the initial antigen pre-
sentation to T cells and/or the differentiation of naive T
cells into effector cells, but not the secondary activation of
antigen-specific T cells. Recently, Zhang et al. (45) re-
ported that depletion of NK cells augments disease severity,
T cell proliferation, and production of Th1 cytokines in
experimental autoimmune encephalomyelitis, a prototype
Th1-mediated condition. These novel data are in contrast
to the general paradigm that NK cells are required for opti-
mal activation of Th1-like immune responses. It can be
speculated that depletion of NK cells has similar effects in
our experimental model, causing a switch from Th2 to
Th1. However, our data on systemic IgE and IgG2a levels,
BALF cytokine levels, and CD31 splenic T cell cytokine
production fail to indicate this. The early appearance of
NK cells at the site of immunization (17) and their ability
to produce a variety of cytokines implicate these cells in
several critical steps in the development of the acquired im-
mune response to allergens. One possibility is that NK cells
provide mediators that critically influence differentiation of
resting APCs to an activated phenotype with the T cell co-
stimulatory capacity that is required for the exaggerated T
cell activation in allergic pulmonary inflammation (5, 46).
Indeed, both isoforms of B7 on APCs are upregulated by
IFN-g (47), a cytokine which may derive in part from NK
cells. Other immunoregulatory functions of NK cells may
be attributed to their capacity to produce IL-5 (12). In-
deed, Walker et al. are now demonstrating that IL-5 pro-
duced by NK cells may contribute to eosinophil infiltration
in a mouse model of allergic peritonitis (48). Although it
appears likely that NK cells exert their effects by cytokine
production, it cannot be excluded that NK cells influence
the immunization phase by cytolytic mechanisms. It has
been shown that APCs, i.e., dendritic cells and macro-
phages, are highly susceptible to lysis by NK cells, which
thus might modulate the antigen presentation (49). Further
studies are warranted to elucidate details of cellular and
molecular interplays that may explain the present observa-
tions.
The present data suggest the possibility that the increased
NK cell activity that has been demonstrated in asthma (19–
21) reflects a predisposition of individuals with high NK
cell activity to develop exaggerated T cell responses to in-
haled antigens and hence to be at risk of developing
asthma. In epidemiological investigations, a predisposition
to develop asthma has been strongly associated with ele-
vated levels of serum IgE (50). Interestingly, a correlation
between NK cell activity and total serum IgE levels has
been observed in healthy subjects (51).
In conclusion, the present data indicate that NK cells
may have a critical role in immunization and subsequent
development of allergen-induced airway inflammation.
These new data suggest the possibility of a pathogenic role
for the increased number of NK cells observed in asthma
and suggest that NK cell activity may be one of the factors
governing the development of allergic eosinophilic airway
disease.
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